Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ALRN

Aileron Therapeutics Inc

Apr 15 • 04:00PM ET

5.93

Dollar change -0.21
Percentage change -3.42	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ONEQ VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.85	Insider Own	18.15%	Shs Outstand	4.89M	Perf Week	-4.35%
Market Cap	29.00M	Forward P/E	-	EPS next Y	-	Insider Trans	0.60%	Shs Float	4.00M	Perf Month	7.23%
Income	-12.94M	PEG	-	EPS next Q	-	Inst Own	41.83%	Short Float	0.88%	Perf Quarter	50.70%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-10.63%	Short Ratio	0.97	Perf Half Y	386.07%
Book/sh	2.47	P/B	2.40	EPS next Y	-	ROA	-64.61%	Short Interest	0.04M	Perf Year	275.32%
Cash/sh	2.47	P/C	2.40	EPS next 5Y	2.10%	ROE	-76.36%	52W Range	1.01 - 7.12	Perf YTD	94.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	37.03%	ROI	-115.56%	52W High	-16.71%	Beta	2.25
Dividend TTM	-	Quick Ratio	7.88	Sales past 5Y	-	Gross Margin	-	52W Low	487.13%	ATR (14)	0.49
Dividend Ex-Date	-	Current Ratio	7.88	EPS Y/Y TTM	56.30%	Oper. Margin	0.00%	RSI (14)	52.66	Volatility	7.94% 8.66%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	9.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	71.31%	Payout	-	Rel Volume	0.43	Prev Close	6.14
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Apr 15 AMC	Avg Volume	36.34K	Price	5.93
SMA20	0.58%	SMA50	11.77%	SMA200	102.36%	Trades		Volume	15,719	Change	-3.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-24-17	Initiated	William Blair	Outperform
Jul-24-17	Initiated	Jefferies	Buy	$20
Jul-24-17	Initiated	BofA/Merrill	Buy	$19

Apr-15-24 05:20PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Aileron Therapeutics Announces CEO Transition (GlobeNewswire) -5.41%
Feb-15-24 04:05PM	Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event (GlobeNewswire)
Feb-01-24 04:30PM	Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 (GlobeNewswire) -6.06%
Oct-31-23 12:30PM	Aileron Therapeutics Announces Acquisition of Lung Therapeutics (PR Newswire)
09:55AM	Loading…
Apr-04-23 09:55AM	Bears are Losing Control Over Aileron Therapeutics, Inc. (ALRN), Here's Why It's a 'Buy' Now (Zacks)
Mar-14-23 09:55AM	Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +12.12%
Feb-22-23 11:49AM	Cancer drugmaker down to 3 employees after trial failure (American City Business Journals) +6.16%
Feb-21-23 02:50PM	Aileron Therapeutics Shelves Development On Chemoprotection Agent, Shares Fall (Benzinga) -37.77%
08:30AM	Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives (GlobeNewswire)
Dec-29-22 12:00PM	What Makes Aileron Therapeutics, Inc. (ALRN) a New Buy Stock (Zacks)
Nov-30-22 07:00AM	Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Nov-24-22 09:55AM	Aileron Therapeutics, Inc. (ALRN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-10-22 08:00AM	Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split (GlobeNewswire) -11.98%
Nov-04-22 12:00PM	Aileron Therapeutics, Inc. (ALRN) Moves to Buy: Rationale Behind the Upgrade (Zacks) +10.94%
08:15AM	Loading…
Nov-01-22 08:15AM	Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Oct-26-22 06:05AM	Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference (GlobeNewswire) -5.83%
Sep-30-22 08:41AM	Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 (GlobeNewswire) -8.13%
Sep-22-22 08:00AM	Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire)
Sep-06-22 07:00AM	Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-15-22 04:15PM	Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Aug-01-22 07:51AM	Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer (GlobeNewswire) -15.68%
Jul-08-22 08:31AM	Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 (GlobeNewswire)
Jun-29-22 09:46AM	Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting (Benzinga) -27.14%
06:30AM	Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer (GlobeNewswire)
May-19-22 07:00AM	Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer (GlobeNewswire)
06:40AM	3 Oversold Biotech Stocks to Buy Now (InvestorPlace)
May-17-22 07:00AM	Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +12.92%
May-13-22 07:00AM	Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 (GlobeNewswire) +9.15%
May-11-22 07:57AM	Will Aileron Therapeutics (NASDAQ:ALRN) Spend Its Cash Wisely? (Simply Wall St.)
12:43PM	Loading…
May-10-22 12:43PM	Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting (GlobeNewswire)
May-05-22 04:15PM	Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Apr-21-22 09:40AM	Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year? (Zacks) -6.12%
08:00AM	Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations (GlobeNewswire)
Apr-05-22 09:40AM	Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year? (Zacks) +5.88%
Mar-28-22 04:20PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire) -7.41%
Mar-22-22 08:04AM	Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Jan-27-22 01:38PM	Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ... (GuruFocus.com) -9.48%
Jan-05-22 08:04AM	Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones (GlobeNewswire) -7.27%
Jan-04-22 08:45AM	Aileron Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
07:00AM	CEO Presenting on the Emerging Growth Conference on January 5 Register Now (GlobeNewswire)
Dec-30-21 04:32AM	As Aileron Therapeutics, Inc.'s market cap (NASDAQ:ALRN) drops to US$47m, insiders might be questioning their decision to buy earlier this year (Simply Wall St.)
Dec-20-21 10:56AM	Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs (GlobeNewswire)
Nov-12-21 07:50AM	Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights (GlobeNewswire) -6.13%
Oct-07-21 09:22AM	Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity (GlobeNewswire)
Sep-30-21 04:30PM	Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 (GlobeNewswire)
Sep-16-21 02:33PM	Aileron Stock Is Trading Lower After Data Presentation For Chemoprotective Agent (Benzinga) -6.09%
08:15AM	Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924s Best-in-Class Potential as a Chemoprotective Agent (GlobeNewswire)
Sep-10-21 08:30AM	Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924 (GlobeNewswire) +6.72%
Sep-07-21 04:05PM	Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference (GlobeNewswire)
Aug-27-21 09:48AM	Aileron Unveils Initial Data For Its Chemo Protective Agent (Benzinga)
07:45AM	Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th Annual Scientific Meeting (GlobeNewswire)
Aug-11-21 04:20PM	Aileron Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Jul-08-21 08:15AM	Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jul-01-21 01:39PM	Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings (Benzinga)
08:00AM	Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire)
Jun-30-21 09:33AM	Hedge Funds Are Betting On Aileron Therapeutics, Inc. (ALRN) (Insider Monkey) -6.02%
Jun-24-21 07:00AM	Aileron Therapeutics to be Added to the Russell Microcap® Index (GlobeNewswire) +8.66%
May-19-21 07:00AM	Aileron Therapeutics to Host KOL Virtual Investor Event Discussing Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities (GlobeNewswire)
May-11-21 04:18PM	Aileron Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-24-21 04:36PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-04-21 08:30AM	Aileron Therapeutics to Present at 2021 H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) -5.52%
Mar-02-21 07:00AM	Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (GlobeNewswire) -7.78%
Jan-11-21 06:30AM	Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners (GlobeNewswire) +42.22%
Jan-06-21 09:30AM	Aileron Therapeutics Announces $35.9 Million Registered Direct Offering (GlobeNewswire) -5.38%
Dec-23-20 03:41AM	Medicenna vs Aileron: Which Penny Stock Could Surge Over 200%? (TipRanks) +9.43%
Dec-21-20 08:00AM	Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities (GlobeNewswire)
Dec-14-20 08:32AM	New Strong Sell Stocks for December 14th (Zacks) -6.62%
Dec-01-20 10:12AM	New Strong Sell Stocks for December 1st (Zacks)
Nov-29-20 08:33PM	Is Aileron Therapeutics, Inc. (ALRN) A Good Stock To Buy? (Insider Monkey)
Nov-24-20 08:28AM	New Strong Sell Stocks for November 24th (Zacks)
Nov-19-20 10:02AM	New Strong Sell Stocks for November 19th (Zacks)
Nov-12-20 07:03PM	Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights (GlobeNewswire)
Oct-24-20 04:35AM	Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium (GlobeNewswire)
Oct-20-20 09:24AM	Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium (GlobeNewswire) +31.61%
Oct-13-20 08:30AM	Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher (Zacks) +15.15%
Oct-12-20 07:00AM	Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium (GlobeNewswire) +6.45%
Sep-21-20 06:07PM	Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital (GlobeNewswire) -5.88%
Sep-10-20 08:45AM	Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference (GlobeNewswire)
Aug-25-20 01:25PM	The Zacks Analyst Blog Highlights: Emergent Biosolutions, Horizon, Novavax, Celldex and Aileron Therapeutics (Zacks)
Aug-05-20 04:10PM	Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) +34.55%
Aug-04-20 03:31PM	3 Strong Buy Penny Stocks That Could Go Boom (TipRanks) +21.33%
Aug-03-20 08:10AM	Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August (GlobeNewswire)
08:00AM	Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924 (GlobeNewswire)
Jun-29-20 08:30AM	Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan (GlobeNewswire) +7.27%
Jun-12-20 11:42AM	Largest Insider Trades of the Week (GuruFocus.com)
Jun-10-20 09:54AM	Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares (GlobeNewswire) +10.62%
Jun-04-20 09:15AM	Aileron Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -15.27%
Jun-03-20 04:01PM	Aileron Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +12.93%
Jun-02-20 10:22AM	The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics (Zacks) -21.09%
07:45AM	The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs (Benzinga)
Jun-01-20 08:34AM	5 Top Stocks Up 100%+ in May With More Room to Run (Zacks) -9.26%
07:00AM	Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer (GlobeNewswire)
May-27-20 08:30AM	Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent (GlobeNewswire) +5.91%
May-11-20 08:30AM	Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) +6.81%
Apr-22-20 08:30AM	Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020 (GlobeNewswire)
Mar-30-20 04:16PM	Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results (GlobeNewswire)
Dec-20-19 05:45PM	Hedge Fund Sentiment Is Unchanged On Aileron Therapeutics, Inc. (ALRN) (Insider Monkey) +11.08%
Dec-19-19 06:07AM	Are Insiders Buying Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock? (Simply Wall St.) +6.60%
Dec-18-19 08:30AM	Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer (GlobeNewswire) +8.16%

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WINDSOR JAMES BRIAN	President and COO	Dec 15 '23	Buy	3.37	225	758	225	Dec 18 05:56 PM
WINDSOR JAMES BRIAN	President and COO	Nov 20 '23	Buy	1.97	5,076	9,987	5,122	Nov 21 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALRN

Aileron Therapeutics Inc

Upgrade your FINVIZ experience